Strs Ohio trimmed its holdings in shares of ANI Pharmaceuticals Inc (NASDAQ:ANIP) by 11.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 12,000 shares of the specialty pharmaceutical company’s stock after selling 1,500 shares during the quarter. Strs Ohio owned about 0.10% of ANI Pharmaceuticals worth $540,000 as of its most recent filing with the SEC.
A number of other large investors have also added to or reduced their stakes in ANIP. Teachers Retirement System of The State of Kentucky increased its holdings in ANI Pharmaceuticals by 99.5% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 2,005 shares of the specialty pharmaceutical company’s stock valued at $113,000 after buying an additional 1,000 shares during the period. Bessemer Group Inc. bought a new position in ANI Pharmaceuticals in the 3rd quarter valued at about $138,000. Truvestments Capital LLC bought a new position in ANI Pharmaceuticals in the 3rd quarter valued at about $152,000. Paloma Partners Management Co bought a new position in ANI Pharmaceuticals in the 3rd quarter valued at about $239,000. Finally, MetLife Investment Advisors LLC increased its holdings in ANI Pharmaceuticals by 55.6% in the 3rd quarter. MetLife Investment Advisors LLC now owns 6,140 shares of the specialty pharmaceutical company’s stock valued at $347,000 after buying an additional 2,195 shares during the period. 62.35% of the stock is currently owned by institutional investors and hedge funds.
NASDAQ:ANIP traded down $0.49 during mid-day trading on Monday, hitting $55.37. 209 shares of the company’s stock were exchanged, compared to its average volume of 52,811. The company has a debt-to-equity ratio of 1.04, a current ratio of 3.34 and a quick ratio of 2.49. ANI Pharmaceuticals Inc has a fifty-two week low of $36.92 and a fifty-two week high of $72.81. The company has a market cap of $662.28 million, a PE ratio of 15.34 and a beta of 2.51.
Several equities analysts have commented on ANIP shares. ValuEngine raised shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 23rd. Cantor Fitzgerald set a $74.00 price target on shares of ANI Pharmaceuticals and gave the company a “buy” rating in a report on Friday, December 28th. BidaskClub raised shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, October 19th. Finally, Canaccord Genuity set a $70.00 price target on shares of ANI Pharmaceuticals and gave the company a “buy” rating in a report on Friday, November 9th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $71.00.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and hydrocortisone enema and cortenema to treat ulcerative colitis.
See Also: Coverage Ratio
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.